Altimmune's intranasal COVID-19 vaccine shows sterilizing potential

By The Science Advisory Board staff writers

May 10, 2021 -- Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose.

Sterilizing immunity is considered critical for blocking transmission of the virus, the company said. Data came from a preclinical mouse study that showed a single dose of AdCOVID blocked virus uptake in vaccinated mice compared to unvaccinated counterparts.

Altimmune plans to release phase I data from an AdCOVID clinical trial in June. The trial is evaluating three dose levels of the vaccine, according to the firm.

Altimmune touts data on intranasal COVID-19 vaccine candidate
Altimmune is highlighting data from a clinical study of AdCOVID, the company's single-dose, intranasal COVID-19 vaccine candidate.
Lonza dedicates manufacturing suite to Altimmune's COVID-19 vaccine
Altimmune has expanded its previously established manufacturing collaboration with Lonza for AdCOVID, Altimmune's single-dose, intranasal COVID-19 vaccine...
Altimmune begins trial of nasal COVID-19 vaccine
Altimmune has begun enrollment in a phase I clinical trial of AdCOVID, a single-dose, intranasal COVID-19 vaccine candidate.
Altimmune submits IND for single dose intranasal COVID-19 vaccine
Altimmune has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to begin a phase I clinical trial of its...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter